<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00145002</url>
  </required_header>
  <id_info>
    <org_study_id>JCOG9801</org_study_id>
    <secondary_id>C000000066</secondary_id>
    <nct_id>NCT00145002</nct_id>
  </id_info>
  <brief_title>A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL)</brief_title>
  <official_title>Phase III Study of VCAP-AMP-VECP vs. Biweekly CHOP in Aggressive Adult T-cell Leukemia-lymphoma (ATLL): Japan Clinical Oncology Group Study, JCOG9801.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japan Clinical Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Japan Clinical Oncology Group</source>
  <brief_summary>
    <textblock>
      To test the superiority of VCAP-AMP-VECP regimen over biweekly-CHOP in aggressive ATLL in
      terms of survival benefit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nothing to describe.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1998</start_date>
  <completion_date>December 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
  </secondary_outcome>
  <enrollment>130</enrollment>
  <condition>Adult T-cell Leukemia</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biweekly-CHOP with G-CSF and intrathecal prophylaxis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of ATL was made based on seropositivity for HTLV-I by either enzyme-linked
             immunosorbent assay or particle agglutination assay, and histologically- and/or
             cytologically-proven peripheral T-cell malignancy

          2. Aggressive ATL, i.e., acute-, lymphoma- or unfavorable chronic-type ATL

          3. Aged 15-69 years

          4. No prior chemotherapy or radiotherapy

          5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-3 or 4 as a result
             of hypercalcemia

          6. Preserved organ (bone marrow, liver, kidney, heart and lung) functions

          7. All patients were required to provide written informed consent

        Exclusion Criteria:

          1. Diabetes mellitus necessitating treatment with insulin

          2. Active systemic infection

          3. Cardiac disorders expected to become worse as a result of the DOX-containing regimen

          4. Acute hepatitis, chronic hepatitis or liver cirrhosis

          5. Positive for HBs Ag or anti-HCV Ab

          6. Active concurrent malignancy

          7. Other serious medical or psychiatric conditions

          8. Pregnancy or breast feeding

          9. Central nervous system involvement by ATL cells
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masao Tomonaga, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Nagasaki University Graduate School of Biomedical Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nagasaki University Graduate School of Biomedical Science</name>
      <address>
        <city>Nagasaki</city>
        <zip>852-8523</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.jcog.jp/</url>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2005</study_first_submitted>
  <study_first_submitted_qc>September 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <keyword>ATLL</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>phase III study</keyword>
  <keyword>VCAP-AMP-VECP</keyword>
  <keyword>biweekly-CHOP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

